^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MOR107

    i
    Other names: MOR 107, MOR107, LP2, LP2-3, selective AT2 receptor agonistic lanthipeptide, MOR-107
    Associations

    News

    Trials
    Company:
    Novartis
    Drug class:
    Angiotensin type 2 receptor agonist
    Associations

    News

    Trials
    3years
    LP2, a cyclic angiotensin-(1-7) analog extended with an N-terminal D-lysine, impairs growth of patient-derived xenografts of colorectal carcinoma in mice. (PubMed, Peptides)
    LP2 acted synergistically with 5-FU and the EGFR inhibitor erlotinib. Taken together, the extremely low dose of LP2 at which antitumor activity is exerted, the synergism with selected drugs and, together with its excellent specificity, safety and stability, warrant further evaluation of LP2's inhibitory potential of colorectal cancer.
    Preclinical • Journal
    |
    ATR (Ataxia telangiectasia and Rad3-related protein)
    |
    erlotinib • 5-fluorouracil • MOR107